Clinical relevance of molecular characteristics in Burkitt lymphoma differs according to age
-
Published:2022-07-06
Issue:1
Volume:13
Page:
-
ISSN:2041-1723
-
Container-title:Nature Communications
-
language:en
-
Short-container-title:Nat Commun
Author:
Burkhardt BirgitORCID, Michgehl UlfORCID, Rohde JonasORCID, Erdmann TabeaORCID, Berning PhilippORCID, Reutter Katrin, Rohde MariusORCID, Borkhardt ArndtORCID, Burmeister ThomasORCID, Dave SandeepORCID, Tzankov AlexandarORCID, Dugas Martin, Sandmann SarahORCID, Fend FalkoORCID, Finger Jasmin, Mueller Stephanie, Gökbuget Nicola, Haferlach TorstenORCID, Kern Wolfgang, Hartmann WolfgangORCID, Klapper WolframORCID, Oschlies IlskeORCID, Richter Julia, Kontny UdoORCID, Lutz MathiasORCID, Maecker-Kolhoff BrittaORCID, Ott German, Rosenwald Andreas, Siebert Reiner, von Stackelberg ArendORCID, Strahm BrigitteORCID, Woessmann WilhelmORCID, Zimmermann Martin, Zapukhlyak Myroslav, Grau MichaelORCID, Lenz GeorgORCID
Abstract
AbstractWhile survival has improved for Burkitt lymphoma patients, potential differences in outcome between pediatric and adult patients remain unclear. In both age groups, survival remains poor at relapse. Therefore, we conducted a comparative study in a large pediatric cohort, including 191 cases and 97 samples from adults. While TP53 and CCND3 mutation frequencies are not age related, samples from pediatric patients showed a higher frequency of mutations in ID3, DDX3X, ARID1A and SMARCA4, while several genes such as BCL2 and YY1AP1 are almost exclusively mutated in adult patients. An unbiased analysis reveals a transition of the mutational profile between 25 and 40 years of age. Survival analysis in the pediatric cohort confirms that TP53 mutations are significantly associated with higher incidence of relapse (25 ± 4% versus 6 ± 2%, p-value 0.0002). This identifies a promising molecular marker for relapse incidence in pediatric BL which will be used in future clinical trials.
Funder
Deutsche Kinderkrebsstiftung The work was supported by the Mediziner Kolleg of the Medical Faculty of the University of Muenster (K.R.) and the Clinician-Scientist Program of the Cells In Motion Cluster of Excellence (J.R.). The work was supported by the Clinician-Scientist Program of the Cells In Motion Cluster of Excellence, University of Muenster. The work was supported by the Mediziner Kolleg of the Medical Faculty of the University of Muenster.
Publisher
Springer Science and Business Media LLC
Subject
General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry,Multidisciplinary
Reference80 articles.
1. Burkhardt, B. et al. The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence. Br. J. Haematol. 131, 39–49 (2005). 2. Miles, R. R., Arnold, S. & Cairo, M. S. Risk factors and treatment of childhood and adolescent Burkitt lymphoma/leukaemia. Br. J. Haematol. 156, 730–743 (2012). 3. Teras, L. R. et al. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J. Clin. 66, 443–459 (2016). 4. Morton, L. M. et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 107, 265–276 (2006). 5. Hecht, J. L. & Aster, J. C. Molecular biology of Burkitt’s lymphoma. J. Clin. Oncol. 18, 3707–3721 (2000).
Cited by
26 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|